Deletion of the Bacillus anthracis capB homologue in Francisella tularensis subspecies tularensis generates an attenuated strain that protects mice against virulent tularaemia

Journal of Medical Microbiology
Stephen MichellPetra C F Oyston

Abstract

As there is currently no licensed vaccine against Francisella tularensis, the causative agent of tularaemia, the bacterium is an agent of concern as a potential bioweapon. Although F. tularensis has a low infectious dose and high associated mortality, it possesses few classical virulence factors. An analysis of the F. tularensis subspecies tularensis genome sequence has revealed the presence of a region containing genes with low sequence homology to part of the capBCADE operon of Bacillus anthracis. We have generated an isogenic capB mutant of F. tularensis subspecies tularensis SchuS4 and shown it to be attenuated. Furthermore, using BALB/c mice, we have demonstrated that this capB strain affords protection against significant homologous challenge with the wild-type strain. These data have important implications for the development of a defined and efficacious tularaemia vaccine.

References

Aug 1, 1977·The Journal of Hygiene·A M Hood
Sep 1, 1991·Infection and Immunity·A H FortierC A Nacy
Dec 1, 1989·Microbial Pathogenesis·L S AnthonyP A Kongshavn
May 1, 1989·Reviews of Infectious Diseases·A Tärnvik
Mar 1, 1996·FEMS Immunology and Medical Microbiology·A NorqvistG Sandström
Oct 13, 2000·Lancet·A S KhanS Lillibridge
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
May 29, 2003·FEMS Microbiology Letters·Igor GolovliovVitaly Pavlov
May 1, 1961·Archives of Internal Medicine·S SASLAWS CARHART
Nov 20, 2004·Nature Reviews. Microbiology·Petra C F OystonRichard W Titball
Jan 11, 2005·Nature Genetics·Pär LarssonRichard W Titball
May 13, 2006·Molecular Microbiology·Thomas Candela, Agnès Fouet
Aug 4, 2006·Applied and Environmental Microbiology·Maya MerabishviliDaniele Daffonchio
Mar 29, 2007·Proceedings of the National Academy of Sciences of the United States of America·David S WeissDenise M Monack
Apr 11, 2007·Infection and Immunity·Jingliang SuJing-Ren Zhang
Jul 17, 2008·Journal of Medical Microbiology·Petra C F Oyston
Oct 28, 2008·Journal of Bacteriology·Jacques RavelDavid A Rasko
Nov 5, 2008·Infection and Immunity·Aiping QinBarbara J Mann
Feb 19, 2009·Infection and Immunity·Karin L MeibomAlain Charbit
Jun 2, 2009·Canadian Journal of Microbiology·Thomas CandelaAgnès Fouet
Oct 20, 2009·Vaccine·Petra C F Oyston

❮ Previous
Next ❯

Citations

Jun 13, 2012·Microbiology and Molecular Biology Reviews : MMBR·Crystal L JonesDavid S Weiss
Oct 19, 2012·Future Microbiology·Elodie RamondAlain Charbit
Jan 19, 2016·Frontiers in Cellular and Infection Microbiology·Hannah M Rowe, Jason F Huntley
Jun 15, 2013·Vaccine·Mark E Marohn, Eileen M Barry
Nov 6, 2018·The FEBS Journal·Sneha RamaswamyAnnalisa Pastore
Jun 6, 2018·Frontiers in Cellular and Infection Microbiology·Qingmei Jia, Marcus A Horwitz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.